COMMUNIQUÉS West-GlobeNewswire

Devenez membre PREMIUM

Accèdez sans limite aux 15 000 actualités du site
et recevez gratuitement chaque semaine,
la Newsletter Santé log avec les actus Santé à ne pas manquer !

S'abonner
29€ TTC/an

Je suis déjà membre PREMIUM

Se connecter

Innocoll and Gurnet Point Announcement relating to the Scheme becoming Effective
24/07/2017 - 15:26
NOT FOR RELEAS E, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE [...]
Corning and Gerresheimer Collaborate to Deliver New Corning Valor(TM) Glass to the Pharmaceutical Packaging Market
24/07/2017 - 14:30
Remarkable glass innovation enables enhanced quality parenteral packaging CORNING, N.Y. and DUSSELDORF, GERMANY; JULY 24, 2017 - Corning Incorporated (NYSE: GLW) and Gerresheimer AG announce that they are accelerating [...]
Minerva Neurosciences Announces Departure of Directors
24/07/2017 - 14:30
WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, [...]
Novo Nordisk A/S - Share repurchase programme
24/07/2017 - 11:35
Bagsværd, Denmark, 24 July 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
LIDDS: Clarification regarding signed research agreement
24/07/2017 - 08:55
With reference to press release LIDDS signs research agreement with major European pharma company, published 21 July 2017 at 10:00 CET, we hereby announce that the agreement party is Ferring Pharmaceuticals. Contact [...]
DEINOVE renforce la fonction de Business Développement avec l'arrivée de Sébastien Enault
24/07/2017 - 08:30
Sébastien Enault apporte à la Société une expérience confirmée dans la mise en place de collaborations dans le domaine pharmaceutique et notamment dans celui des anti-infectieux. Montpellier, le 24 juillet 2017 (8h30 [...]
DEINOVE strengthens its Business Development activity with the arrival of Sébastien Enault
24/07/2017 - 08:30
Sébastien Enault brings to the Company a proven track record in the development of collaborations in the pharmaceutical field and, in particular, in the anti-infective field. Montpellier, 24 July 2017 (8:30am CEST) - [...]
Xbrane Biopharma AB: Spherotide granted Market Authorization in Iran
24/07/2017 - 08:00
Press release 2017-07-24 Xbranes partner Pooyesh Darou has been granted Market Authorization for sales and marketing of Spherotide 1 month formulation in Iran under the local brand name Microrelin®. "This is a major [...]
ABLYNX ANNOUNCES WARRANT EXERCISE
24/07/2017 - 07:00
REGULATED INFORMATION GHENT, Belgium, 24 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an [...]
VALNEVA reçoit le statut de "Fast Track" de la FDA pour son candidat vaccin contre la maladie de Lyme VLA15
24/07/2017 - 07:00
Valneva reçoit le statut de "Fast Track" de la FDA pour son candidat vaccin contre la maladie de Lyme VLA15 Lyme est la maladie infectieuse transmise par vecteur qui se développe le plus rapidement aux Etats-Unis, selon [...]
VALNEVA Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15
24/07/2017 - 07:00
Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15 Lyme disease is the fastest growing vector-borne infectious disease in the United States, according to the CDC; Currently, there [...]
Innocoll Announcement Relating to the Outcome of the Court Sanction Hearing
21/07/2017 - 14:54
NOT FOR RELEAS E, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE [...]
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
21/07/2017 - 13:30
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent ® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis - First investigational targeted biologic in the European Union to receive [...]
Sanofi et Regeneron obtiennent un avis favorable du CHMP pour Dupixent® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère de l'adulte
21/07/2017 - 13:30
Sanofi et Regeneron obtiennent un avis favorable du CHMP pour Dupixent ® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère de l'adulte - Premier traitement biologique expérimental ciblé à obtenir [...]
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
21/07/2017 - 13:19
Recommendation based on largest trial in FLT3-mutated AML to date, showing 23% reduction in the risk of death with Rydapt treatment regimen[1] If approved, Rydapt would represent the first targeted treatment for newly [...]
uniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program
21/07/2017 - 13:00
-- Commercial-Scale Batches of AMT-060 Successfully Produced in Accordance with Good Manufacturing Practices in Lexington, MA Facility -- -- Manufacturing Process to be Leveraged in Huntington's Program, With Production [...]
LIDDS signs research agreement with major European pharma company
21/07/2017 - 10:00
LIDDS has entered into a research agreement with a major pharmaceutical company which has an exclusive option right to leverage the NanoZolid® technology for the development of an injectable, controlled-release [...]
Oriola Corporation's Half Year Financial Report January-June 2017
21/07/2017 - 07:30
Oriola Corporation Stock Exchange Release 21 July 2017 at 8.30 a.m. Oriola Corporation's Half Year Financial Report January - June 2017 Financial performance April-June 2017, continuing operations Invoicing decreased by [...]
Alligator Bioscience AB: Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy
21/07/2017 - 07:03
Press release, July 21, 2017 Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy Strategic partnership will advance development of a novel [...]

Pages